AHNS 10Th International Conference on Head & Neck Cancer
Total Page：16
File Type：pdf, Size：1020Kb
AHNS 10TH INTERNATIONAL CONFERENCE ON HEAD & NECK CANCER “Survivorship through Quality & Innovation” JULY 22-25, 2021 • VIRTUAL CONFERENCE AHNS PRESIDENT: Cherie-Ann Nathan, MD, FACS CONFERENCE/DEVELOPMENT CHAIR: Robert Ferris, MD, PhD PROGRAM CHAIR: Eben Rosenthal, MD PROFFERED PAPERS CHAIR: Ellie Maghami, MD POSTER CHAIR: Maie St. John, MD Visit www.ahns2021.org for more information. WELCOME LETTER Dear Colleagues, The American Head and Neck Society (AHNS) is pleased to invite you to the virtual AHNS 10th International Conference on Head and Neck Cancer, which will be held July 22-25, 2021. The theme is Survivorship through Quality & Innovation and the scientific program has been thoughtfully designed to bring together all disciplines related to the treatment of head and neck cancer. Our assembled group of renowned head and neck surgeons, radiologists and oncologists have identified key areas of interest and major topics for us to explore. The entire conference will be presented LIVE online July 22-25, 2021. We encourage you to attend the live sessions in order to engage with the faculty and your colleagues. After the live meeting, all of the meeting content will be posted on the conference site and remain open for on-demand viewing through October 1, 2021. Attendees may earn up to 42.25 AMA PRA Category 1 Credit(s)TM as well as earn re- quired annual part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery’s Continu- ing Certification program (formerly known as MOC). At the conclusion of the activity, participants will be able to: • Assess and apply therapeutic options for the head and neck, salivary gland, and thyroid cancer patient in a multidisci- plinary environment • Assess emerging research that lead to better understanding of the pathogenesis of head and neck cancer and its treatment • Assess and apply the process, outcomes, and quality of delivering care to head and neck cancer patients • Recognize the vital role of nurses, speech language pathologists, audiologists, nutritionists, social workers, pain spe- cialists, mental health practitioners, physical therapists, dental oncologists in achieving maximal functional outcomes and increase interdisciplinary cooperation Robert Ferris, MD, PhD Eben Rosenthal, MD Cherie-Ann Nathan, MD, FACS AHNS 2021 Conference Chair AHNS 2021 Program Chair AHNS President GENERAL INFORMATION AHNS Accreditation Statement The American Head & Neck Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Head & Neck Society designates this other [online live and online enduring] activity for a maximum of 42.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn their required annual part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery’s Continuing Certification program (formerly known as MOC). It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of recognizing participation. AHNS 10th International Conference on Head and Neck Cancer • July 22 - 25, 2021 • www.ahns2021.org 2 GENERAL INFORMATION Who Should Attend? Head and Neck Surgeons Pathologists Otolaryngologists Residents and Fellows Plastic Surgeons Clinical Investigators Surgical and Medical Oncologists Molecular and Cellular Biologists Dentists & Oral Surgeons Advance Practice Providers Radiation Oncologists Speech and Language Pathologists Radiologists Allied Health Professionals Learning Objectives At the conclusion of the activity, participants will be able to: A. Assess and apply therapeutic options for the head and neck, salivary gland, and thyroid cancer patient in a multidisciplinary environment, including: • Induction chemotherapy and concurrent chemoradiotherapy, and how these treatments impact oncologic and functional outcomes of patient with advanced head and neck cancer. • Novel radiation delivery, and the benefits and shortcomings of methods such as Intensity Modulated Radiotherapy (IMRT) with comparison to proton therapy. • Emerging molecular-targeted agents, and their efficacy and role in the treatment of head and neck cancer, including thyroid cancer. • Surgical treatments, including the impact of breakthroughs in technology leading to robotic surgery, endoscopic approaches to the neck and thyroid gland, image-guided treatment of skull base neoplasms, sentinel node mapping. • Advances in radiology and imaging will be reviewed: Describe approaches to reduce sampling error in during surgery or pathological assessment of the tumor specimen of pre-operative and post-operative optical imaging technologies. • Review of new reconstructive approaches and compare with conventional strategies to compare outcomes and cost, and new powered instrumentation and hemostatic devices. B. Assess emerging research that lead to better understanding of the pathogenesis of head and neck cancer and its treatment, including: • New breakthroughs for disease detection, pre-treatment staging, and assessment of treatment response. • High throughput laboratory approaches to analyze tumors and biofluids including whole genome sequencing, cDNA microrrays, array CGH, SNP arrays and integrative genomic. • The significance of human papilloma virus elements and or antibodies in tumors and biofluids. • Pre-clinical evaluation of novel therapeutics. • Early detection of oral pre-malignancy and cancer and chemopreventive approaches. • Newly discovered biomarkers and their utility in treatment selection. • In addition, attendees with research careers may also be able to find new collaborators, develop new research protocols (including clinical trials), and participate in and improve existing protocols and trials. C. Assess and apply the process, outcomes, and quality of delivering care to head and neck cancer patients, including: • The value of treatment guidelines including the NCCN treatment guidelines in improving patient care. • How to measure patient-reported outcomes and maximize their utility. • How to establish a surgical quality and performance monitoring program. • How cost-effectiveness is important to consider in considering novel treatments. • The Physician Quality Reporting Initiative (PQRI) in head and neck cancer care. • Incorporating quality into trainee/medical student education. • The burden of caring for H&N cancer in the developing and international community. D. Recognize the vital role of nurses, speech language pathologists, audiologists, nutritionists, social workers, pain specialists, mental health practitioners, physical therapists, dental oncologists in achieving maximal functional outcomes and increase interdisciplinary cooperation. • Use of ancillary services to improve physical and emotional well-being. • Use of NP led survivorship clinics that allow more time for patient counseling. • Genetic counselors to provide help with patients suffering from germ line mutations. • Incorporating quality into trainee/medical student education. AHNS 10th International Conference on Head and Neck Cancer • July 22 - 25, 2021 • www.ahns2021.org 3 GUESTS OF HONOR Conference Chair Guest of Honor EUGENE MYERS, MD Dr. Eugene N. Myers comes from a long line of physicians including his Grandfather, his Father and three Uncles. HIs Father, David, was the Chairman of the Department of Otorhinology in the Temple University School of Medicine. Dr. Myers received a B.S in Economics from the Wharton School of the University of Pennsylvania and his M.D. from Temple University School of Medicine. He interned at Mt.Sinai School of Medicine in New York City followed by a residency in Otolaryngology at the Massachusetts Eye and Ear Infirmary in Boston. This was followed by military service as a Captain in the U.S. Army stationed in the 97th General Hospital in Frankfurt, Germany. He then served as a Special Fellow in Head and Neck Surgery with Dr.John Conley in New York City. Dr. Myers was appointed Chairman of the Department of Otolaryngology in the University of Pittsburgh School of Medicine in 1972 and under his leadership transformed it into a world renowned Department. He estimates that he did 9,000 operations during the 33 years as Chairman. He has made many contributions including the development and implementation of the treatment method to properly manage patients who have extracapsular spread of cancer in their cervical lymph nodes. Dr. Myers academic achievements include the publication of more than 300 peer reviewed articles, 20 textbooks, including the popular Cancer of the Head and Neck and Operative Otolaryngology-Head and Neck Surgery, 150 book chapters, more than 750 lectures, panels and round tables, including 48 eponymous lectures. Dr. Myers is Past President of the American Board of Otolaryngology, the American Academy of Otolaryngology-Head and Neck Surgery, the American Society of Head and Neck Surgeons, the American Laryngological Association, and the Pan American Association of Otolaryngology-Head and Neck Surgery. He was the founder of the International Department of the American Academy of Otolaryngology-Head and Neck Surgery and organized a world wide network of National Societies which includes our Academy. He is an Honorary Member of more than 20 National Societies